CELYAD ONCOLOGY (CYAD.BR) Forecast, Price Target & Analyst Ratings
EBR:CYAD • BE0974260896
0.32 EUR
-0.02 (-5.33%)
Last: Mar 10, 2026, 07:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CELYAD ONCOLOGY (CYAD.BR).
Forecast Snapshot
Consensus Price Target
N/A
N/A
Next Earnings Forecast
Release DateN/A
ChartMill Buy Consensus
42.22%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of €0.32 to mean target of N/A, Based on 9 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
42.22%
CYAD.BR was analyzed by 9 analysts. The buy percentage consensus is at 42. So analysts seem to be rather negative about CYAD.BR.
In the previous month the buy percentage consensus was at a similar level.
CYAD.BR was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | ||
|---|---|---|---|---|
| Revenue YoY % growth | 102K | 186K 82.35% | ||
| EBITDA YoY % growth | -4.333M 82.58% | -8.75M -101.94% | -5.42M 38.06% | |
| EBIT YoY % growth | -5.773M 78.12% | -9.544M -65.32% | -5.87M 38.50% | |
| Operating Margin | N/A | -9,356.86% | -3,155.91% | |
| EPS YoY % growth | N/A | N/A | N/A |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CELYAD ONCOLOGY / CYAD.BR Forecast FAQ
What is the number of analysts for CYAD stock?
The number of analysts covering CELYAD ONCOLOGY (CYAD.BR) is 9.